University of Kentucky, Children’s Hospital of Philadelphia and Mitochon Pharmaceuticals Awarded NIH Grant for Traumatic Brain Injury Studies

Tags:   NIH  

BLUE BELL, Pa.--(BUSINESS WIRE)--Mitochon Pharmaceuticals today announced that they, in partnership with the University of Kentucky (UK) and Children’s Hospital of Philadelphia (CHOP), were awarded a $3.2M National Institutes of Health grant to study Mitochon’s mitochondrial targeted drug therapies for treating Traumatic Brain Injury (TBI). This important award, along with the Company’s open IND, will help pave the way for new potential therapies for treating the devastating effects of brain trauma.

“We are delighted to receive this grant. Traumatic Brain Injury affects the daily lives of millions of people with no treatments to curb the devastating effects post-trauma for both civilians and military.” – commented Dr. John Geisler, Ph.D., Mitochon’s Chief Scientific Officer. Mitochon’s compound MP-201, has previously been shown by TBI expert Dr. Patrick Sullivan, Ph.D. at the UK to significantly reduce brain volume loss and restore cognition after two weeks of treatment post injury. The $3.2M award was made to Dr. Patrick Sullivan at UK and Dr. Todd Kilbaugh, M.D. at the CHOP to conduct more advanced studies with MP-201 in models of TBI.

MP-101 and MP-201 are mitochondrial targeted, once-a-day oral therapies that have been shown to shield cells from damage caused by a host of degenerative processes (genetic, non-genetic, auto-immune and injury). In preclinical studies, these compounds have exhibited protective and functional benefits in disease models. These include brain volume sparing in Huntington’s Disease, preserving dopamine neurons in Parkinson’s Disease, and sustaining motor skills in Amyotrophic Lateral Sclerosis (ALS).

About Mitochon Pharmaceuticals

Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and aging. Mitochon’s lead programs, MP-101 and MP-201, specifically harnesses the power of the mitochondria to provide broad neural protection. These compounds, through micro dosing, elicit mild increases in energy expenditure that result in strengthening cellular survival. Investors include: Ben Franklin Technology Partners, Cures Within Reach and YT Angels. Additional Information:

“Research reported in this press release was supported by the NIH/National Institute of Neurological Disorders and Stroke under award number R01NS112693. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.”


Company Contact: Robert Alonso, President & CEO Mitochon Pharmaceuticals, Inc. 215-313-3905

Company Contact: Robert Alonso, President & CEO Mitochon Pharmaceuticals, Inc. 215-313-3905